1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of breast cancer
LT4376848TActive Publication Date: 2026-10-26CELCUITY INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- LT4376848P0
- Authority / Receiving Office
- LT · LT
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-07-25
- Filing Date
- 2022-07-25
- Publication Date
- 2026-10-26
- Estimated Expiration
- 2042-07-25
Need to check novelty before this filing date? Find Prior Art
No text content released.
